Roth Capital Has Negative Estimate for MNMD Q3 Earnings

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) – Equities research analysts at Roth Capital cut their Q3 2025 earnings per share (EPS) estimates for Mind Medicine (MindMed) in a report released on Tuesday, November 19th. Roth Capital analyst J. Wittes now forecasts that the company will earn ($0.35) per share for the quarter, down from their prior forecast of ($0.34). The consensus estimate for Mind Medicine (MindMed)’s current full-year earnings is ($1.35) per share. Roth Capital also issued estimates for Mind Medicine (MindMed)’s FY2025 earnings at ($1.38) EPS, FY2026 earnings at ($1.61) EPS, FY2027 earnings at $1.27 EPS and FY2028 earnings at $4.67 EPS.

A number of other research firms also recently weighed in on MNMD. Leerink Partners initiated coverage on Mind Medicine (MindMed) in a research report on Monday, October 14th. They issued an “outperform” rating and a $20.00 target price for the company. Leerink Partnrs upgraded shares of Mind Medicine (MindMed) to a “strong-buy” rating in a report on Friday, October 11th. HC Wainwright reaffirmed a “buy” rating and set a $55.00 target price on shares of Mind Medicine (MindMed) in a report on Monday, November 11th. Finally, Canaccord Genuity Group decreased their target price on shares of Mind Medicine (MindMed) from $16.00 to $14.00 and set a “buy” rating on the stock in a research report on Monday, September 16th. Nine research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $25.38.

Mind Medicine (MindMed) Price Performance

MNMD opened at $7.56 on Friday. The company has a current ratio of 9.00, a quick ratio of 9.00 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $554.37 million, a P/E ratio of -3.35 and a beta of 2.48. The stock has a 50-day moving average price of $6.44 and a 200-day moving average price of $7.13. Mind Medicine has a 12-month low of $2.75 and a 12-month high of $12.22.

Institutional Trading of Mind Medicine (MindMed)

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MNMD. Wealth Enhancement Advisory Services LLC bought a new position in Mind Medicine (MindMed) in the 3rd quarter worth $58,000. Bridgewealth Advisory Group LLC purchased a new position in shares of Mind Medicine (MindMed) during the second quarter valued at about $72,000. Wealth Alliance bought a new position in Mind Medicine (MindMed) in the second quarter worth about $79,000. SG Americas Securities LLC purchased a new stake in Mind Medicine (MindMed) in the third quarter worth about $93,000. Finally, Stoneridge Investment Partners LLC bought a new stake in Mind Medicine (MindMed) during the 3rd quarter valued at approximately $93,000. Hedge funds and other institutional investors own 27.91% of the company’s stock.

Insider Activity at Mind Medicine (MindMed)

In other Mind Medicine (MindMed) news, insider Dan Karlin sold 6,871 shares of the stock in a transaction that occurred on Wednesday, September 25th. The stock was sold at an average price of $5.98, for a total value of $41,088.58. Following the completion of the sale, the insider now owns 344,656 shares in the company, valued at approximately $2,061,042.88. This trade represents a 1.95 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Robert Barrow sold 19,771 shares of the business’s stock in a transaction that occurred on Wednesday, September 25th. The shares were sold at an average price of $5.98, for a total value of $118,230.58. Following the transaction, the chief executive officer now directly owns 545,772 shares in the company, valued at $3,263,716.56. This trade represents a 3.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 28,994 shares of company stock worth $173,384 in the last three months. 2.26% of the stock is owned by insiders.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.